Edmond DE Rothschild Holding S.A. Purchases Shares of 4,503,300 DENTSPLY SIRONA Inc. $XRAY
Edmond DE Rothschild Holding S.A. has acquired a new stake of 4,503,300 shares in DENTSPLY SIRONA Inc., valued at approximately $47.8 million, representing a 2.26% ownership. This move comes as institutional investors now hold 95.7% of the company's stock, and DENTSPLY SIRONA insiders have also recently increased their holdings. The company recently surpassed quarterly earnings expectations but reported a decline in year-over-year revenue, while analysts maintain a consensus "Hold" rating with a target price of $13.38.
Wellspect Launches Surity Urinary Management System | XRAY Stock News
Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY), has launched the Surity™ Urinary Management System in the U.S. This discreet at-home urine collection device is designed to help more than 13 million Americans and their caregivers manage urinary incontinence, complementing the existing Surity™ Female and Male External Catheters. The system offers gentle suction, quiet operation, and carbon filters for odor reduction, aiming to improve comfort and rest, particularly for nighttime use.
DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Bank of America Corp DE
Bank of America Corp DE increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 18.3% in the first quarter, now owning 2.43 million shares valued at $28.2 million. The company reported strong Q1 earnings, beating analyst expectations with $0.52 EPS and $898 million in revenue, despite a 4.1% year-over-year revenue decline. Analysts currently maintain a "Hold" rating on the stock with an average price target of $13.38.
Royal Bank of Canada Raises Holdings in DENTSPLY SIRONA Inc. $XRAY
Royal Bank of Canada significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 137.7% in the first quarter, now owning 256,701 shares valued at approximately $3.0 million. Other institutional investors have also adjusted their holdings, and company insiders recently purchased shares. DENTSPLY SIRONA exceeded quarterly earnings expectations with $0.52 EPS, though revenue saw a slight year-over-year decrease.
DENTSPLY Sirona Inc (XRAY) News, Articles, Events & Latest Updates
DENTSPLY Sirona Inc. (XRAY) reported a Q2 2026 profit, turning around from a loss in the previous year, driven by improved margins and the absence of prior impairment charges. Despite a 4.1% sales decline due to dental weakness, the company's Wellspect division showed growth, and its full-year 2026 guidance was reaffirmed. The article also includes various news items and earnings reports related to XRAY and other companies like Align Technology (ALGN), Envista (NVST), and McKesson (MCK).
Dentsply Sirona (XRAY): Southpoint reports 7M-share, 3.5% ownership in 13G/A
Southpoint Master Fund and its affiliates, including John S. Clark II, have reported a beneficial ownership of 7,000,000 shares, representing a 3.5% stake in Dentsply Sirona Inc. (XRAY). This disclosure was made in an amended Schedule 13G/A filing, indicating shared voting and dispositive power over the shares. The ownership percentage is based on 199,353,876 shares outstanding as of July 24, 2026.
Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile?
DENTSPLY SIRONA Inc. reported mixed Q2 2026 results with lower year-on-year sales but a return to net income, reaffirming its full-year 2026 net sales guidance. The company continued its share buyback program while navigating market expectations that are slightly above its own reaffirmed revenue outlook. The article suggests investors assess whether the company's turnaround strategy, digital platform investments, and share repurchases will effectively address execution risks and drive future growth towards its projected 2029 revenue and earnings targets.
Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript
Dentsply Sirona reported Q2 2026 results with a revenue decline of 4.1% and adjusted EPS flat year-over-year at $0.52, benefiting from a $0.17 per share tariff refund. The company is six months into a 24-month restructuring program focused on customer re-engagement, commercial realignment, and financial discipline, with new CFO John C. Fortson emphasizing operational excellence and debt reduction. While maintaining full-year revenue and adjusted EPS guidance, management expects Q3 revenue to decline sequentially due to seasonality and earnings to be below Q2 levels, excluding the tariff refund.
Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile?
DENTSPLY SIRONA (XRAY) reported Q2 2026 sales of US$898 million, returning to a net income of US$37 million, and reaffirmed its full-year 2026 sales guidance of US$3.5 billion to US$3.6 billion, despite lower year-on-year revenue. The company continued its share buyback program, repurchasing 1.3 million shares for US$12.92 million. This mixed performance, coupled with the reaffirmed guidance, necessitates a reassessment of the company's investment narrative, particularly concerning its turnaround strategy and the impact of revenue pressures on profitability.
DENTSPLY SIRONA (XRAY) gains AQR Capital as 5.22% beneficial owner
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have reported a 5.22% beneficial ownership in DENTSPLY SIRONA Inc. (XRAY), amounting to 10,458,771 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment with shared voting and dispositive power over all shares. The filing details the entities' beneficial ownership, which is not intended to change or influence the control of the issuer.
DS World Las Vegas 2026 connects clinical and laboratory education
Dentsply Sirona World Las Vegas 2026 will offer a comprehensive educational program for dental professionals, connecting clinical expertise, laboratory innovation, and digital workflows to advance patient care. The event, taking place from September 24 to 26, will feature main stage presentations by clinical experts and a dedicated laboratory track with hands-on training and lectures. Attendees can earn continuing education credits, network, and explore the latest innovations in connected dentistry.
The 5 Most Interesting Analyst Questions From Dentsply Sirona’s Q2 Earnings Call
Dentsply Sirona (XRAY) reported Q2 CY2026 earnings, exceeding analyst expectations for revenue and adjusted EPS, though shares declined post-announcement. Management attributed revenue decline to lower sales in key segments and regions, noting the company is in a "turnaround" phase with uneven improvements. Analysts focused on the executive team's readiness, specifics of the growth plan, impact of tariff refunds, U.S. commercial team buildout, and softness in the OIS segment.
DENTSPLY SIRONA (XRAY) CFO awarded 104,200 stock options and 24,014 RSUs
DENTSPLY SIRONA (XRAY) EVP & CFO John C. Fortson was granted 24,014 Restricted Stock Units (RSUs) and 104,200 stock options. The RSUs and stock options vest in one-third annual increments over a three-year period, ending August 10, 2029. The stock options have an exercise price of $12.83 per share and expire on August 10, 2036.
Pacer Advisors Inc. Has $266,000 Stake in DENTSPLY SIRONA Inc. $XRAY
Pacer Advisors Inc. significantly reduced its stake in DENTSPLY SIRONA Inc. by 90.5% in the first quarter, now holding 22,973 shares valued at $266,000. Institutional investors collectively own 95.7% of the company, while analyst ratings are mixed with an average "Hold" and target price of $13.38. DENTSPLY SIRONA reported Q1 EPS of $0.52, exceeding estimates, and revenue of $898 million, despite a 4.1% year-over-year decline.
DENTSPLY SIRONA (XRAY) SVP Frohning reports 802 tax-withheld shares
Andrea L. Frohning, SVP and CHRO of DENTSPLY SIRONA Inc. (XRAY), reported the disposition of 802 shares of common stock on August 7, 2026. These shares were withheld to cover taxes related to the vesting of her Restricted Stock Units and dividend equivalent units. Following this transaction, Frohning directly holds 63,190.618 shares of DENTSPLY SIRONA common stock.
Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today
Dentsply Sirona's (XRAY) stock fell 6.8% after its Q2 2026 earnings report, despite beating profit estimates. The decline was primarily driven by a weak full-year revenue forecast, which came in 1% below analyst consensus, raising concerns about the company's future growth prospects. This negative outlook overshadowed the positive aspects of the current quarter's performance.
DENTSPLY SIRONA Inc. (XRAY) Stock Forecasts
Morningstar has published an analyst report on DENTSPLY SIRONA Inc. (XRAY), stating that its weak recovery momentum remains unchanged due to soft volume impacting results. The report notes that Dentsply Sirona is one of the world’s largest manufacturers of dental equipment and supplies, formed from a 2016 merger. The current price of XRAY is $11.66.
Dentsply's Full Recovery Timeline Looks Uncertain as Tough Market and Competition Put Pressure
Dentsply Sirona, a major dental equipment manufacturer, faces an uncertain recovery due to intense market competition and soft sales volume. The company has invested in its Cerec system and expanded partnerships to adapt, but its competitive edge has been challenged by new entrants. Analysts note weak recovery momentum and a difficult market outlook.
Dentsply Sirona Earnings: Weak Recovery Momentum Unchanged as Soft Volume Weighs on Results
Dentsply Sirona reported a decline in revenue and adjusted EPS for the second quarter, although both figures surpassed FactSet consensus estimates. The company maintained its full-year revenue and EPS guidance, despite the share price dropping 3% after hours. The article highlights that weak recovery momentum and soft volume continue to impact results, making the full recovery timeline uncertain due to market and competition pressures.
Empowered Funds LLC Grows Stake in DENTSPLY SIRONA Inc. $XRAY
Empowered Funds LLC significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 515.3% in the first quarter, now holding 126,601 shares valued at $1.47 million. This comes as DENTSPLY SIRONA reported stronger-than-expected Q2 earnings per share and revenue, though overall revenue declined year-over-year, and 2026 revenue guidance remained cautious. Analyst sentiment is mixed, with a consensus "Hold" rating, while company directors have recently purchased shares.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Recommendation of "Hold" from Analysts
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has an average "Hold" recommendation from analysts, with nine firms rating it Hold, three Sell, and three Buy. The company's Q2 earnings beat expectations with an adjusted EPS of $0.52 and revenue of $898 million, though revenue declined year-over-year. Analysts maintain a cautious outlook for sales, with full-year revenue guidance below consensus despite maintained EPS guidance.
DENTSPLY SIRONA Inc. Stock 12‑Month Price Target Raised to $13.7, Implies 4% Upside
Analysts have raised DENTSPLY SIRONA Inc.'s average 12-month price target from $13.53 to $13.7, suggesting a 4% potential upside based on its closing price on August 6th. The consensus rating from 19 analysts remains "Hold," with a breakdown of 4 Buys, 13 Holds, and 2 Sells. This updated target indicates continued, albeit modest, confidence in the stock's future performance.
Dentsply Sirona Reports $898 Million in Net Sales for Second Quarter 2026
Dentsply Sirona reported net sales of $898 million for the second quarter of 2026, alongside an adjusted earnings per share of $0.52. Despite a 13.2% decline in its orthodontic and implant segment sales, the company maintained its full-year financial outlook, projecting net sales between $3.5 billion and $3.6 billion, and an adjusted EPS of $1.40 to $1.50. The company is actively executing its "Return-to-Growth Action Plan," focusing on strengthening distributor relationships, realigning sales teams, and reinvesting in the business.
DENTSPLY SIRONA (NASDAQ:XRAY) Issues Earnings Results
DENTSPLY SIRONA (NASDAQ:XRAY) announced its quarterly earnings, reporting an adjusted EPS of $0.52, beating consensus estimates of $0.35, with revenue of $898 million, slightly above expectations. Despite this beat, revenue declined 4.1% year-over-year, and the company maintained its 2026 guidance, anticipating sequential declines in Q3 due to seasonality and investments. Analysts hold a consensus "Hold" rating for the stock, with insiders recently increasing their holdings.
Dentsply Sirona Q2 2026 Earnings: Sales Decline as GAAP Margins Recover
Dentsply Sirona reported a Q2 2026 net sales decline of 4.1% to $898 million, though GAAP diluted EPS improved to $0.18 from a prior-year loss, largely due to the absence of impairment charges. While GAAP gross margins and operating cash flow increased significantly, constant-currency sales were down 6.3%, and adjusted operating profitability weakened. The company reiterated its full-year guidance, focusing on its Return-to-Growth Action Plan despite ongoing sales pressure and higher expenses.
DENTSPLY SIRONA (XRAY): First Eagle discloses 851,347-share position in 13G/A
First Eagle Investment Management, LLC has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 851,347 shares in DENTSPLY SIRONA Inc. (XRAY). This position represents 0.4% of the company's common stock, keeping First Eagle below the 5% ownership threshold. The filing indicates First Eagle has sole voting power over 659,032 shares and sole dispositive power over all 851,347 shares.
BRIEF-Dentsply Sirona Q2 Revenue USD 898 Million Vs. IBES Estimate USD 889.8 Million
Dentsply Sirona announced its Q2 revenue reached USD 898 million, surpassing the IBES estimate of USD 889.8 million. This brief report highlights the company's financial performance relative to analyst expectations.
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Posts Q2 Adjusted EPS $0.52 per Share
DENTSPLY SIRONA Inc. (XRAY) announced its Q2 adjusted EPS of $0.52 per share. This earnings flash follows a previous report that the company's Q2 revenue was $898.0M, exceeding FactSet estimates of $889.9M. The company is a diversified manufacturer of professional dental products and technologies.
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Reports Q2 Revenue $898.0M, vs. FactSet Est of $889.9M
DENTSPLY SIRONA Inc. (XRAY) reported its Q2 revenue at $898.0 million, surpassing FactSet's estimate of $889.9 million. The company is a diversified manufacturer of professional dental products and technologies, offering comprehensive solutions across various dental segments. The report also highlights recent company news, including its Q2 2026 earnings call and adjusted EPS.
Dentsply Sirona Reports Second Quarter 2026 Results
Dentsply Sirona announced its financial results for the second quarter of 2026, reporting net sales of $898 million and adjusted EPS of $0.52, in line with expectations. The company reiterated its 2026 outlook for net sales and adjusted EPS, and highlighted progress in its "Return-to-Growth Action Plan," including expanded distributor relationships and share repurchases.
Dentsply Sirona investors brace for earnings amid Medline threat By Investing.com
Dentsply Sirona Inc. is preparing to report second-quarter earnings, facing investor scrutiny over its ability to counter competitive pressure from Medline's expansion into the dental market. Analysts forecast earnings of 35 cents per share and revenue of $889.2 million, representing a significant year-over-year decline. The company's focus on its return-to-growth strategy and leveraging its technology portfolio against potential consumables weakness will be key for investors.
Expanded Medline Sinclair Tech Distribution in Canada Could Be A Game Changer For DENTSPLY SIRONA (XRAY)
DENTSPLY SIRONA recently announced an expanded partnership with Medline Sinclair for full technology portfolio distribution in Canada, effective September 1, 2026. This move could significantly scale DENTSPLY SIRONA's digital dentistry solutions in the Canadian market. The announcement comes ahead of the Q2 2026 earnings report, with investors keen to see how new distribution agreements impact orders and financial performance amidst ongoing pressures.
Arkadios Wealth Advisors Purchases New Stake in DENTSPLY SIRONA Inc. $XRAY
Arkadios Wealth Advisors recently acquired a new stake of 74,961 shares in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $870,000. Despite this new investment and insider purchases totaling over $200,000 in June, analyst sentiment remains cautious, with an average "Hold" rating and a target price of $13.46. The company reported first-quarter revenue of $880 million, exceeding estimates, but earnings per share of $0.27, slightly missing expectations.
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
DENTSPLY SIRONA (XRAY) is scheduled to release its second-quarter 2026 results, with analysts expecting revenues of $883.9 million and earnings of 36 cents per share. The company's "Return-to-Growth" action plan and ongoing investments are key factors, alongside challenges from dealer inventory adjustments, tariffs, and weaker demand in certain segments and European markets. Investors will be watching for updates on U.S. recovery, new distribution agreements, and the impact of restructuring on future profitability.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DENTSPLY SIRONA
Faruqi & Faruqi, LLP is investigating potential claims against DENTSPLY SIRONA Inc. (NASDAQ: XRAY) on behalf of investors who suffered losses exceeding $75,000 between February 28, 2022, and November 6, 2024. The investigation stems from allegations that Dentsply made misleading statements and failed to disclose issues related to its Byte aligners, including targeting contraindicated patients and causing severe injuries. Investors have until January 27, 2025, to seek the role of lead plaintiff in the federal securities class action lawsuit.
Dentsply Sirona’s Endo Forum 2026 explores advances in endodontic care
Dentsply Sirona's Endo Forum 2026 brought together over 80 endodontic experts in Spain to discuss advancements, emerging trends, and future innovations in endodontic care. The event facilitated dialogue between clinicians and Dentsply Sirona's product development teams, leading to discussions on digital workflows, new products like the RECIPROC Minima file system, and new approaches to coronal restoration. This collaboration aims to inform future innovations and educational initiatives that align with clinical practice, ultimately supporting the preservation of natural teeth.
Price to book forward of DENTSPLY SIRONA, Inc. – BX:DY2
This article provides financial data for DENTSPLY SIRONA, Inc. (BX:DY2), specifically its price-to-book forward ratio. It indicates that the market is closed for this stock and no trades have occurred. The content is primarily a data point with no further analysis or discussion.
Does Expanding Medline Sinclair Partnership in Canada Strengthen DENTSPLY SIRONA's (XRAY) Digital Dentistry Edge?
DENTSPLY SIRONA Inc. is expanding its partnership with Medline Sinclair in Canada, allowing the distributor to offer DENTSPLY SIRONA's full technology portfolio, not just consumables, starting September 1, 2026. This move aims to broaden access to DENTSPLY SIRONA's digital dentistry solutions across Canada, leveraging Medline Sinclair's national network. While this expansion is seen as helpful for near-term growth, the article notes that it doesn't directly address immediate risks such as weak sales in key categories and tariff-driven margin pressure.
DENTSPLY SIRONA Inc (XRAY) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of DENTSPLY SIRONA Inc (XRAY), noting its current financial score is 6.13, ranking it 172 out of 199 in the Healthcare Equipment & Supplies industry. Despite a weak overall financial status, the company shows high operating efficiency. Its latest quarterly revenue saw a 0.11% year-over-year increase, and net profit surged by 150.00% year-over-year.
Dentsply Sirona Number of Employees 2026 | Employee Count & Headcount Data
Dentsply Sirona (NASDAQ: XRAY) had approximately 13,897 employees worldwide as of March 2026, representing a 4.7% decline since 2023. The company is actively hiring with 802 job postings in 2026, though new postings per month have decreased. The workforce is concentrated in North America, with an average salary of $71,653, and overall employee sentiment is negative and declining.
DENTSPLY SIRONA (XRAY) Expected to Release Earnings on Thursday
DENTSPLY SIRONA (NASDAQ:XRAY) is scheduled to release its Q2 2026 earnings after market close on Thursday, August 6th. Analysts are anticipating earnings of $0.36 per share and revenue of $889.2140 million. The company previously reported Q1 2026 EPS of $0.27, missing estimates, but exceeding revenue expectations with $880.00 million.
DENTSPLY SIRONA Inc (XRAY) Q1 2026 Earnings Report - Results, Call & Slides
DENTSPLY SIRONA (XRAY) reported its Q1 2026 earnings, missing EPS estimates at $4.71 against a consensus of $4.85, but beating revenue expectations with $15.36 billion. The company maintained its full-year 2026 guidance, citing improved operating cash flow, debt reduction, early cost savings from restructuring, and new product launches as positives. Despite these strengths, the company faced challenges including constant-currency revenue declines, significant margin compression, softness in several key segments, and tariff-related pressures.
Dentsply Sirona Is Maintained at Neutral by Piper Sandler
Piper Sandler has reiterated its "Neutral" rating for Dentsply Sirona. This indicates the firm's ongoing assessment that the stock is expected to perform in line with the market.
XRAY Maintained by Piper Sandler -- Price Target Raised to $14.0
Piper Sandler has maintained a Neutral rating for Dentsply Sirona (XRAY) and raised its price target from $13.00 to $14.00, signaling cautious optimism for the company's future. Despite current unprofitability, XRAY is considered 26.3% undervalued according to its GF Value™ of $18.99, and insider activity shows net buying, suggesting potential for recovery. The company, a major dental equipment manufacturer, has a moderate GF Score™ of 59/100, with strong valuation but weak growth.
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Dentsply Sirona Inc. (NASDAQ: XRAY) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss legal options, including seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can lead to more transparent and accountable company management, potentially enhancing shareholder value.
DENTSPLY SIRONA Inc (XRAY) Institutional Confidence
DENTSPLY SIRONA Inc's institutional confidence score is 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding decreased by 9.16% quarter-over-quarter to 111.69%, with First Eagle Investment being the largest shareholder. The article lists top institutional shareholders and their recent share changes.
Does Expanding Medline Sinclair Partnership in Canada Strengthen DENTSPLY SIRONA's (XRAY) Digital Dentistry Edge?
DENTSPLY SIRONA is expanding its partnership with Medline Sinclair in Canada to offer its full technology portfolio, aiming to broaden access to its digital dentistry solutions. This move is part of a larger strategy to widen the reach of DENTSPLY SIRONA's technology and address recent revenue pressures and leadership changes. While the expansion is seen as directionally helpful for near-term growth, investors are encouraged to consider the company's full narrative and risk factors beyond distribution partnerships.
Dentsply Sirona Expands Medline Sinclair Partnership in Canada
Dentsply Sirona has expanded its partnership with Medline Sinclair in Canada, making the company the exclusive distributor of Dentsply Sirona's endodontic and restorative products in the Canadian market. This collaboration aims to enhance product accessibility and support for dental professionals across Canada. The expansion builds on their existing relationship, ensuring a broader reach for Dentsply Sirona's dental solutions.
Does Expanding Medline Sinclair Partnership in Canada Strengthen DENTSPLY SIRONA's (XRAY) Digital Dentistry Edge?
DENTSPLY SIRONA is expanding its partnership with Medline Sinclair in Canada to offer its full technology portfolio, aiming to broaden access to its digital dentistry solutions. This move builds on previous US distribution expansions and is intended to boost near-term growth, though challenges like revenue pressure and tariff impacts remain. The company's future performance hinges on how effectively these partnerships translate into higher utilization and profitability.
Southpoint Capital Advisors LP Buys Shares of 10,000,000 DENTSPLY SIRONA Inc. $XRAY
Southpoint Capital Advisors LP acquired a new stake of 10 million shares in DENTSPLY SIRONA Inc. (XRAY) during the first quarter, valued at approximately $116 million. This purchase represents 4.99% of DENTSPLY SIRONA and 2.4% of Southpoint Capital's portfolio. Institutional ownership of DENTSPLY SIRONA remains high at 95.7%, with various other funds and company directors also increasing their positions despite mixed analyst sentiment and the company slightly missing earnings expectations.
